Esperer Bio-Research Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
- Paid Up Capital ₹ 4.40 Cr
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -57.26%
- Profit Growth -502.02%
- Ebitda -417.00%
- Net Worth -314.58%
- Total Assets -47.01%
About Esperer Bio-Research
Esperer Bio-Research Private Limited (EBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 16 August 2018 (Six years and six months 7 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 4.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkataktyayani Gorantla, Shubhankar Karmakar, Raktim Chattopadhyay, and Two other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304MH2018PTC312841
- Company No.
312841
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Esperer Bio-Research?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkataktyayani Gorantla  | Director | 23-Feb-2021 | Current |
| Shubhankar Karmakar | Director | 01-Jan-2020 | Current |
| Raktim Chattopadhyay | Director | 16-Aug-2018 | Current |
| Sohilkumar Tandel | Director | 16-Aug-2018 | Current |
| Sudipta Chattopadhyay | Director | 12-Mar-2020 | Current |
Financial Performance of Esperer Bio-Research.
Esperer Bio-Research Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 57.26% decrease. The company also saw a substantial fall in profitability, with a 502.02% decrease in profit. The company's net worth observed a substantial decline by a decrease of 314.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Esperer Bio-Research?
In 2023, Esperer Bio-Research had a promoter holding of 96.67% and a public holding of 3.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Manthan Wellness LlpVenkataktyayani Gorantla is a mutual person
- Cogent Defi Private Limited
Venkataktyayani Gorantla is a mutual person
- Rslk Dine And Delivery Private Limited
Shubhankar Karmakar is a mutual person
- Ps Lab Biosciences Private Limited
Shubhankar Karmakar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Esperer Bio-Research?
Esperer Bio-Research has a workforce of 12 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esperer Bio-Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esperer Bio-Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
